ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.532,68
-1,33%
S&P 500
5.942,47
1,26%
US Dollar vs BRL
6,1822
0,00%
Bitcoin
98.447,36
0,35%
Brent Oil
76,495
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Citius Pharmaceuticals Inc (CTXR)

  7. Citius Pharmaceuticals Inc (CTXR) Notícias

CTXR

Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTXR
DataHoraFonteTítuloCódigoCompanhia
27/12/202419:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
27/12/202419:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTXRCitius Pharmaceuticals Inc
27/12/202419:00PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
25/11/202410:03PR Newswire (US)Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to ApprovalNASDAQ:CTXRCitius Pharmaceuticals Inc
22/11/202411:00PR Newswire (US)Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock SplitNASDAQ:CTXRCitius Pharmaceuticals Inc
18/11/202418:05PR Newswire (US)Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
18/11/202410:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CTXRCitius Pharmaceuticals Inc
15/11/202415:30PR Newswire (US)Citius Pharmaceuticals Announces $3 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
12/11/202419:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTXRCitius Pharmaceuticals Inc
11/11/202410:45PR Newswire (US)Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid TumorsNASDAQ:CTXRCitius Pharmaceuticals Inc
05/09/202417:30PR Newswire (US)Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CTXRCitius Pharmaceuticals Inc
05/09/202409:30PR Newswire (US)Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologyNASDAQ:CTXRCitius Pharmaceuticals Inc
16/08/202417:34Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:CTXRCitius Pharmaceuticals Inc
14/08/202419:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CTXRCitius Pharmaceuticals Inc
12/08/202418:28PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
12/08/202417:51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
12/08/202417:22PR Newswire (US)Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.NASDAQ:CTXRCitius Pharmaceuticals Inc
12/08/202409:00PR Newswire (US)Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming DevelopmentsNASDAQ:CTXRCitius Pharmaceuticals Inc
09/08/202408:30GlobeNewswire Inc.TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
08/08/202407:59PR Newswire (US)Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
05/08/202409:00PR Newswire (US)Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.NASDAQ:CTXRCitius Pharmaceuticals Inc
05/08/202409:00GlobeNewswire Inc.TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius PharmaceuticalsNASDAQ:CTXRCitius Pharmaceuticals Inc
10/07/202410:10PR Newswire (US)Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage CandidatesNASDAQ:CTXRCitius Pharmaceuticals Inc
29/05/202409:30PR Newswire (US)Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
21/05/202408:00PR Newswire (US)Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202417:05PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
10/05/202409:30PR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
30/04/202417:05PR Newswire (US)Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
26/04/202409:00PR Newswire (US)Citius Pharmaceuticals Announces $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
11/04/202409:30PR Newswire (US)Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTXR

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
USIM5
USIMINAS PNA
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
BRSR6
BANRISUL PNB
BOV
INBR32
Inter &
BOV
GFSA3
GAFISA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados